Analyst RecommendationAnalyst reiterates a Buy rating on CytoSorbents Corporation with a significant potential upside, reflecting confidence in the company's stock performance.
Product PotentialDrugSorb, a product by CytoSorbents, is expected to meet an unmet need in the market, indicating a strong market potential and opportunity for growth.
Regulatory MilestoneCompletion of the STAR-T trial and anticipation of positive top-line data could be a strong catalyst for regulatory submission and commercial launch, which may boost the stock value.